Eikon Therapeutics

This early-stage clinical trial is testing a new oral medication called IMP1734 in people with advanced solid tumors, including breast, ovarian, and prostate cancers. The study aims to find the safest and most effective dose and see how well the drug fights cancer. Participants w…

This study is testing whether adding an experimental drug called EIK1001 to standard chemotherapy and immunotherapy helps people with advanced lung cancer. It's for 70 adults with stage 4 non-small cell lung cancer who haven't had any previous drug treatment for their advanced di…

This early-stage study aims to find a safe and effective dose of a new drug called EIK1005 for people with advanced solid tumors that have spread or cannot be removed by surgery. Researchers will test EIK1005 by itself and combined with an existing immunotherapy drug (pembrolizum…

This study is testing if adding an experimental drug called EIK1001 to the standard first treatment (pembrolizumab) works better for controlling advanced melanoma. About 740 adults with newly diagnosed, advanced melanoma will receive either the new combination or the standard tre…